Article

Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB

2025-02-27

Abstract excerpt

CAR T therapy for solid tumors is limited by a lack of safe and uniformly expressed cell-surface targets. Here, we identify the MiT fusion-driven protein GPNMB as being highly, homogeneously, and stably expressed in primary and relapsed translocation-positive alveolar soft part sarcoma (ASPS) and renal cell carcinoma (tRCC). We developed a GPNMB-targeting CAR T therapy called GCAR1 that shows activity against pati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7626a28-33f0-50f4-9915-486fa0b5b282
DOI: 10.1101/2025.02.26.24319604

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMBDOI 10.1101/2025.02.26.24319604Read

Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesisSemantic proximity Read

SCAN-ACT: Adoptive T Cell Therapy Target Discovery Through Single-Cell TranscriptomicsSemantic proximity Read

An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying translocation RCCSemantic proximity Read

Tunneling CARs: Increasing CAR T tumor infiltration through the overexpression of <i>MMP7</i> and <i>SPP1</i>Semantic proximity Read

CAR-T-drug conjugate against solid tumorSemantic proximity Read

Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agentsSemantic proximity Read

An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying SFPQ-TFE3 driven translocation RCCSemantic proximity Read

Pediatric Patient-Derived-Xenograft development in MAPPYACTS – international pediatric cancer precision medicine trial in relapsed and refractory tumorsSemantic proximity Read

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancersSemantic proximity Read

You complete me: tumor cell-myeloid cell nuclear fusion as a facilitator of organ-specific metastasisSemantic proximity Read

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor modelSemantic proximity Read

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy targetSemantic proximity Read